Triple inhaler for COPD with heart risk
Part of Lungs & breathing clinical trials.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have a diagnosis of COPD (confirmed by a breathing test).
- You are a current or former smoker with at least a 10 pack-year smoking history.
- You have a certain level of eosinophils (a type of white blood cell) in your blood.
- You have a score of at least 10 on a COPD symptoms questionnaire.
- You have at least one heart-related condition or risk factor (like high blood pressure, diabetes, or a history of heart disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a triple inhaler (BDP/FF/GB) works for people with severe COPD in Brazil. It may help those who have had at least one flare-up in the past year.
This study compares two ways to deliver long-acting bronchodilator medications for COPD: a nebulizer (machine that turns liquid medicine into a mist) versus a handheld inhaler. The goal is to see which method works better for people with moderate to severe COPD symptoms.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.